Clinical Trial: A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis

U.S., March 29 -- ClinicalTrials.gov registry received information related to the study (NCT06900192) titled 'A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis' on Feb. 03.

Brief Summary: A study of alloHCT with Orca-Q for the treatment of primary progressive multiple sclerosis (MS).

Study Start Date: March, 2025

Study Type: INTERVENTIONAL

Condition: Primary Progressive Multiple Sclerosis Multiple Sclerosis Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progressive

Intervention: BIOLOGICAL: Orca-Q

Allogeneic (donor) stem cell graft

DRUG: myeloablative regimen

Myeloablative regimen of busulfan, fludarabine, and thiotepa.

Recruitment Status: NOT_YET_RECRUITING...